On January 12, 2026, Legend Biotech Corp announced progress in its CARVYKTI® treatment, having treated over 10,000 patients and expanded its market presence to 279 sites worldwide. They aim for profitability in 2025 and expect company-wide operating profit in 2026, with a cash reserve of approximately $1 billion as of September 30, 2025.